Ophthalmology
Volume 115, Issue 12 , Pages 2141-2145.e2 , December 2008

Evaluation of Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy: A Pilot Study

Presented in part at: American Academy of Ophthalmology Annual Meeting, November 2007, New Orleans, Louisiana.

  • Dilraj S. Grewal, MD

      Affiliations

    • Grewal Eye Institute, Chandigarh, India
    • Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Palm Beach Gardens, Florida
    • Corresponding Author InformationCorrespondence: Dilraj S. Grewal, MD, Grewal Eye Institute, SCO 166-169, Sector 9-C, Chandigarh, India 160009
    • ,
  • Rajeev Jain, MD

      Affiliations

    • Grewal Eye Institute, Chandigarh, India
    • ,
  • Harsh Kumar, MD

      Affiliations

    • Grewal Eye Institute, Chandigarh, India
    • ,
  • Satinder Pal Singh Grewal, MD

Received 6 February 2008 ,Revised 3 June 2008 ,Accepted 3 June 2008.

References 

  1. Honjo M, Tanihara H, Kameda T, et al. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48:5549–5557
  2. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101:795–798
  3. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc U K. 1983;103:84–88
  4. Khaw PT, Occleston NL, Schultz G, et al. Activation and suppression of fibroblast function. Eye. 1994;8:188–195
  5. Fontana H, Nouri-Mahdavi K, Lumba J, et al. Trabeculectomy with mitomycin C: outcomes and risk factors for failure in phakic open-angle glaucoma. Ophthalmology. 2006;113:930–936
  6. Singh RP, Goldberg I, Mohsin M. The efficacy and safety of intraoperative and/or postoperative 5-fluorouracil in trabeculectomy and phacotrabeculectomy. Clin Experiment Ophthalmol. 2001;29:296–302
  7. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314–346
  8. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol. 1992;114:544–553
  9. CAT-152 0102 Trabeculectomy Study Group. A phase III study of subconjunctival human anti-transforming growth factor beta (2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007;114:1822–1830
  10. Mead AL, Wong TT, Cordeiro MF, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44:3394–3401
  11. Eibl KH, Banas B, Kook D, et al. Alkylphosphocholines: a new therapeutic option in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2004;45:2619–2624
  12. Meyer-ter-Vehn T, Gebhardt S, Sebald W, et al. p38 inhibitors prevent TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci. 2006;47:1500–1509
  13. Wells AP, Crowston JG, Marks J, et al. A pilot study of a system for grading of drainage blebs after glaucoma surgery. J Glaucoma. 2004;13:454–460
  14. Foster PJ, Aung T, Nolan WP, et al. Defining “occludable” angles in population surveys: drainage angle width, peripheral anterior synechiae, and glaucomatous optic neuropathy in east Asian people. Br J Ophthalmol. 2004;88:486–490
  15. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144–146
  16. Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther. 2007;23:487–491
  17. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma. 2007;16:437–439
  18. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res. 2007;39:121–122
  19. Khaw PT, Chang L, Wong TT, et al. Modulation of wound healing after glaucoma surgery. Curr Opin Ophthalmol. 2001;12:143–148
  20. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18–22
  21. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea. 2003;22:473–477
  22. Jacobi J, Tam BY, Sundram U, et al. Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis. Gene Ther. 2004;11:302–309
  23. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging. 2006;37:148–150
  24. Jampel HD, McGuigan LJ, Dunkelberger GR, et al. Cellular proliferation after experimental glaucoma filtration surgery. Arch Ophthalmol. 1988;106:89–94
  25. Watanabe J, Sawaguchi S, Fukuchi T, et al. Effects of mitomycin C on expression of proliferating cell nuclear antigen after filtering surgery in rabbits. Graefes Arch Clin Exp Ophthalmol. 1997;35:234–240
  26. Wong J, Wang N, Miller JW, Schuman JS. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res. 1994;58:439–451
  27. Kano MR, Morishita Y, Iwata C, et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci. 2005;118:3759–3768
  28. Asahara T, Bauters C, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995;92(suppl):II365–II371
  29. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998;141:1659–1673
  30. Corral CJ, Siddiqui A, Wu L, et al. Vascular endothelial growth factor is more important than basic fibroblastic growth factor during ischemic wound healing. Arch Surg. 1999;134:200–205
  31. Beer PM, Wong SJ, Hammad AM, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina. 2006;26:871–876
  32. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855–859
  33. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158–160
  34. Chalam KV, Gupta SK, Grover S, et al. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol. 2008;18:255–262
  35. Cheung JC, Wright MM, Murali S, Pederson JE. Intermediate-term outcome of variable dose mitomycin C filtering surgery. Ophthalmology. 1997;104:143–149
  36. Perkins TW, Gangnon R, Ladd W, et al. Trabeculectomy with mitomycin C: intermediate-term results. J Glaucoma. 1998;7:230–236
  37. Cillino S, Di Pace F, Casuccio A, et al. Deep sclerectomy versus trabeculectomy with low-dosage mitomycin C: four-year follow-up. Ophthalmologica. 2008;222:81–87

 Manuscript no. 2008-180.

 Financial Disclosure(s): The authors have no proprietary or commercial interests in any materials discussed in this article.

PII: S0161-6420(08)00559-9

doi: 10.1016/j.ophtha.2008.06.009

Ophthalmology
Volume 115, Issue 12 , Pages 2141-2145.e2 , December 2008

Article Tools

* Image Usage & Resolution